| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962924044P | 2019-10-21 | 2019-10-21 | |
| PCT/US2020/056431WO2021080950A1 (en) | 2019-10-21 | 2020-10-20 | Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| Publication Number | Publication Date |
|---|---|
| EP4048668A1 EP4048668A1 (en) | 2022-08-31 |
| EP4048668A4true EP4048668A4 (en) | 2024-03-13 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20879791.0APendingEP4048668A4 (en) | 2019-10-21 | 2020-10-20 | Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| Country | Link |
|---|---|
| US (1) | US20210116454A1 (en) |
| EP (1) | EP4048668A4 (en) |
| JP (1) | JP7662625B2 (en) |
| KR (1) | KR20220103949A (en) |
| CN (1) | CN115175903A (en) |
| AU (1) | AU2020372333A1 (en) |
| BR (1) | BR112022007386A2 (en) |
| CA (1) | CA3154890A1 (en) |
| IL (1) | IL292305A (en) |
| MX (1) | MX2022004688A (en) |
| WO (1) | WO2021080950A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3917517A4 (en) | 2019-01-29 | 2023-01-25 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| JP7581345B2 (en)* | 2019-10-21 | 2024-11-12 | セルジーン コーポレーション | Methods of treating chronic lymphocytic leukemia with 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| IL317218A (en) | 2022-06-06 | 2025-01-01 | Treeline Biosciences Inc | Tricyclic quinolone bcl6 bifunctional degraders |
| TW202415655A (en) | 2022-06-13 | 2024-04-16 | 美商樹線生物科學公司 | 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders |
| AU2023292893A1 (en) | 2022-06-13 | 2025-01-02 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
| CN115261469B (en)* | 2022-06-23 | 2023-03-31 | 山东第一医科大学附属省立医院(山东省立医院) | Application of BRD9 in diagnosis and treatment of chronic lymphocytic leukemia |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019209692A1 (en)* | 2018-04-23 | 2019-10-31 | Celgene Corporation | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma |
| WO2020210418A1 (en)* | 2019-04-12 | 2020-10-15 | Celgene Corporation | Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2521672T3 (en) | 2002-05-17 | 2014-11-13 | Celgene Corporation | Pharmaceutical formulations for cancer treatment |
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| KR20090050107A (en)* | 2006-09-15 | 2009-05-19 | 셀진 코포레이션 | N-methylaminomethyl isoindole compound, method for using same, and composition containing same |
| EP2702410A2 (en)* | 2011-04-29 | 2014-03-05 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| EP3904875B1 (en)* | 2012-06-29 | 2024-11-20 | Celgene Corporation | Methods for determining drug efficacy using ikzf3 (aiolos) |
| KR20230070054A (en)* | 2013-03-15 | 2023-05-19 | 제넨테크, 인크. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
| JP2017503481A (en)* | 2013-12-06 | 2017-02-02 | セルジーン コーポレイション | Methods of treating hematological cancer and the use of biomarkers as predictors of clinical sensitivity to immunomodulatory therapy |
| JP7001614B2 (en)* | 2016-04-06 | 2022-02-03 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Monofunctional intermediate for ligand-gated target proteolysis |
| US20200054639A1 (en)* | 2016-10-31 | 2020-02-20 | Oregon Health & Science University | Combinations of agents to treat hematological malignancies |
| JP7581345B2 (en) | 2019-10-21 | 2024-11-12 | セルジーン コーポレーション | Methods of treating chronic lymphocytic leukemia with 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| CA3154908A1 (en) | 2019-10-21 | 2021-04-29 | Sreenivas S. Bhat | Pharmaceutical compositions comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the sam |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019209692A1 (en)* | 2018-04-23 | 2019-10-31 | Celgene Corporation | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma |
| WO2020210418A1 (en)* | 2019-04-12 | 2020-10-15 | Celgene Corporation | Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| Title |
|---|
| See also references ofWO2021080950A1* |
| Publication number | Publication date |
|---|---|
| EP4048668A1 (en) | 2022-08-31 |
| CN115175903A (en) | 2022-10-11 |
| AU2020372333A1 (en) | 2022-04-28 |
| US20210116454A1 (en) | 2021-04-22 |
| MX2022004688A (en) | 2022-05-10 |
| KR20220103949A (en) | 2022-07-25 |
| JP2022552883A (en) | 2022-12-20 |
| JP7662625B2 (en) | 2025-04-15 |
| WO2021080950A1 (en) | 2021-04-29 |
| BR112022007386A2 (en) | 2022-07-05 |
| IL292305A (en) | 2022-06-01 |
| CA3154890A1 (en) | 2021-04-29 |
| Publication | Publication Date | Title |
|---|---|---|
| EP4048668A4 (en) | Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione | |
| IL287145A (en) | Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione | |
| IL278854B1 (en) | Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile | |
| IL291593A (en) | Methods and compounds for restoring mutant p53 function | |
| IL292266A (en) | Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benz yl)amino)isoindoline-1,3-dione | |
| IL292265B2 (en) | Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione | |
| SA515360022B1 (en) | Salts and solid forms of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same | |
| EP3778030A4 (en) | Automatic grinding machine and grinding method thereof | |
| IL292258A (en) | Pharmaceutical compositions comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the same | |
| IL284680A (en) | Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same | |
| EP3975552A4 (en) | File processing device, file processing method, and program | |
| EP4054578A4 (en) | Combination therapy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide | |
| EP4031676A4 (en) | Methods and materials for identifying and treating membranous nephropathy | |
| EP3993394A4 (en) | File processing device, file processing method, and program | |
| HK40077318A (en) | Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione | |
| HK40066611A (en) | Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione | |
| AU2022300184A1 (en) | Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline-1,3-dione | |
| HK40108967A (en) | Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline-1,3-dione | |
| IL284665A (en) | Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same | |
| HK40051930A (en) | Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile | |
| HK40077317A (en) | Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione | |
| GB202016291D0 (en) | Batting pieces for paper piecing projects and related methods | |
| HK40077320A (en) | Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising the same and their use | |
| HK40079627A (en) | Pharmaceutical compositions comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the same | |
| HK40108837A (en) | Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3yl)-4-(2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent | Free format text:STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE | |
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase | Free format text:ORIGINAL CODE: 0009012 | |
| STAA | Information on the status of an ep patent application or granted ep patent | Free format text:STATUS: REQUEST FOR EXAMINATION WAS MADE | |
| 17P | Request for examination filed | Effective date:20220420 | |
| AK | Designated contracting states | Kind code of ref document:A1 Designated state(s):AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR | |
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code | Ref country code:HK Ref legal event code:DE Ref document number:40077318 Country of ref document:HK | |
| A4 | Supplementary search report drawn up and despatched | Effective date:20240213 | |
| RIC1 | Information provided on ipc code assigned before grant | Ipc:G01N 33/574 20060101ALI20240207BHEP Ipc:A61K 45/06 20060101ALI20240207BHEP Ipc:A61K 31/5377 20060101ALI20240207BHEP Ipc:A61P 35/00 20060101ALI20240207BHEP Ipc:C07D 407/14 20060101ALI20240207BHEP Ipc:C07D 403/14 20060101AFI20240207BHEP | |
| RAP3 | Party data changed (applicant data changed or rights of an application transferred) | Owner name:CELGENE CORPORATION | |
| STAA | Information on the status of an ep patent application or granted ep patent | Free format text:STATUS: EXAMINATION IS IN PROGRESS |